About Cochlear Limited (ASX:COH)
Cochlear Limited is engaged in providing implantable hearing solutions. The Company's implant systems comprise an implant, which is inserted during surgery and an external sound processor. The Company operates through three segments, based on geographical basis: Americas, EMEA and Asia Pacific. Americas includes the United States, Canada and Latin America. EMEA includes Europe, Middle East and Africa. Asia Pacific includes Australasia and Asia. The Company's products and solutions include Cochlear implants, such as Nucleus 6 System and Aqua+; Bone conduction implants, such as Baha Attract and Baha Connect; Acoustic implant solutions, such as Cochlear Carina System, Cochlear MET System and Cochlear Codacs System, and Cochlear True Wireless range, such as Cochlear WIRELESS Mini Microphone 2, Cochlear Wireless Mini Microphone 2+, Cochlear Wireless Phone Clip and Cochlear Wireless TV Streamer. The Company sells its products in over 100 countries.
Industry, Sector and Symbol:
- Trailing EPS: A$3.89
- Net Margins: 17.41%
- Return on Equity: 43.42%
- Return on Assets: 21.12%
- Outstanding Shares: 57,430,000
Frequently Asked Questions for Cochlear Limited (ASX:COH)
What is Cochlear Limited's stock symbol?
Cochlear Limited trades on the ASX under the ticker symbol "COH."
Who are some of Cochlear Limited's key competitors?
Some companies that are related to Cochlear Limited include Smith & Nephew plc (SNN), Ramsay Health Care Limited (RHC), Merck KGaA (MRK), AEGON (AGN), Kite Pharma (KITE), Sonic Healthcare Limited (SHL), Ionis Pharmaceuticals (IONS), Valeant Pharmaceuticals International (VRX), Shire-Nps Pharmaceuticals (NPSP), MEDNAX (MD), Premier (PINC), Ansell Limited (ANN), Enerplus Corp (ERF), Mallinckrodt Public Limited Company (MNK), Primary Health Care Limited (PRY), Intrexon (XON), ProMetic Life Sciences (PLI) and Canfor Pulp Products (CFX).
Who are Cochlear Limited's key executives?
Cochlear Limited's management team includes the folowing people:
- Diggory William Howitt, President, Chief Executive Officer, Executive Director
- Christopher Michael Smith, Chief Executive Officer, Executive Director (Age 54)
- Brent Cubis, Chief Financial Officer
- Anthony Bishop, President - Asia Pacific
- Richard Brook, President - European Region, Middle East and Africa Region
- Tony Manna, President, Americas Region
- Stuart Sayers, President - Services
- Dean Phizacklea, Senior Vice President, Global Marketing
- Jan Janssen, Senior Vice President - Research and Development
- Katharine McLennan, Senior Vice President - People and Culture
What is Cochlear Limited's stock price today?
One share of Cochlear Limited stock can currently be purchased for approximately A$181.13.
How big of a company is Cochlear Limited?
Cochlear Limited has a market capitalization of $10.42 billion.
How can I contact Cochlear Limited?
Cochlear Limited's mailing address is 1 University Avenue Macquarie University, SYDNEY, NSW 2109, Australia. The company can be reached via phone at +61-2-94286555.
MarketBeat Community Rating for Cochlear Limited (ASX COH)MarketBeat's community ratings are surveys of what our community members think about Cochlear Limited and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Cochlear Limited (ASX:COH) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Analysts' Consensus Price Target: ||N/A|
Consensus Price Target History for Cochlear Limited (ASX:COH)
Analysts' Ratings History for Cochlear Limited (ASX:COH)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Cochlear Limited (ASX:COH)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Cochlear Limited (ASX:COH)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Cochlear Limited (ASX:COH)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Cochlear Limited (ASX COH)
No insider trades for this company have been tracked by MarketBeat.com
Latest Headlines for Cochlear Limited (ASX COH)
Financials are not available for this stock.